APVO

Aptevo Therapeutics Inc

• TipRanks·05/14 15:00

  Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Aptevo Therapeutics (APVO)

• TipRanks·05/13 16:25

  Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

• Seeking Alpha·05/13 13:35

  Aptevo Therapeutics reports Q1 results

• PUBT·05/13 12:09

  Aptevo says RAINIER trial on track for 2026 completion, Phase 2 dose selection

• TipRanks·05/07 06:10

  Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial

• TipRanks·05/06 20:52

  Aptevo Highlights Strong Phase 1b AML Trial Results

• Benzinga·05/06 12:10

  Aptevo Therapeutic Announces 87% clinical benefit rate And 81% Remission Rate In Its RAINIER Frontline Acute Myeloid Leukemia Trial, RAINIER Remains On Schedule For 2026 Completion And Phase 2 Dose Selection

• PUBT·05/06 12:09

  Aptevo says mipletamig combo shows 81% remission in frontline AML trial cohort 5

• TipRanks·03/27 15:25

  Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)

• TipRanks·03/26 12:20

  Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year

• TipRanks·03/26 12:20

  Aptevo Therapeutics sees cash runway into 4Q26

• Seeking Alpha·03/26 12:08

  Aptevo Therapeutics GAAP EPS of -$87.27

• Reuters·03/26 12:06

  Aptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million

• Reuters·03/23 12:40

  Aptevo highlights mipletamig AML data showing 79% remission rate

• Reuters·03/19 12:06

  Aptevo Therapeutics to present at Roth Conference and BIO-Europe Spring